FY2025 EPS Estimates for Evolus, Inc. (NASDAQ:EOLS) Lowered by HC Wainwright

Evolus, Inc. (NASDAQ:EOLS – Get Rating) – Stock analysts at HC Wainwright reduced their FY2025 earnings estimates for shares of Evolus in a research note issued on Thursday, January 19th. HC Wainwright analyst D. Tsao now expects that the company will earn $0.60 per share for the year, down from their prior estimate of $0.71. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Evolus’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for Evolus’ FY2027 earnings at $1.64 EPS.

Evolus (NASDAQ:EOLS – Get Rating) last announced its quarterly earnings data on Tuesday, November 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.05). Evolus had a negative return on equity of 141.07% and a negative net margin of 56.88%. The firm had revenue of $33.90 million for the quarter, compared to the consensus estimate of $36.94 million.

Several other equities analysts have also recently issued reports on the company. Mizuho raised their price objective on Evolus from $15.00 to $17.00 and gave the stock a “buy” rating in a research note on Thursday. SVB Leerink raised their target price on Evolus from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Thursday. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.67.

Evolus Stock Performance

Shares of EOLS opened at $11.05 on Friday. The business’s fifty day moving average price is $7.70 and its 200 day moving average price is $9.09. Evolus has a 12-month low of $5.06 and a 12-month high of $14.34. The stock has a market capitalization of $621.53 million, a PE ratio of -7.78 and a beta of 1.83. The company has a debt-to-equity ratio of 2.45, a current ratio of 2.26 and a quick ratio of 1.84.

Institutional Investors Weigh In On Evolus

A number of hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Evolus during the second quarter valued at $125,000. AdvisorShares Investments LLC acquired a new position in shares of Evolus during the second quarter valued at $198,000. Bender Robert & Associates acquired a new position in shares of Evolus during the second quarter valued at $291,000. Swiss National Bank acquired a new position in shares of Evolus during the second quarter valued at $989,000. Finally, SG Americas Securities LLC acquired a new position in shares of Evolus during the third quarter valued at $95,000. 45.41% of the stock is currently owned by institutional investors.

About Evolus

(Get Rating)

Evolus, Inc is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.